Results 281 to 290 of about 1,885,895 (335)
Some of the next articles are maybe not open access.
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Cancer Treatment Reviews, 2018Approximately 30-50% of advanced HER2-positive breast cancer patients will develop central nervous system (CNS) metastases, with an annual risk of around 10%, and a half of them will die from brain progression.
R. Duchnowska, S. Loibl, J. Jassem
semanticscholar +1 more source
FLT3 Tyrosine Kinase Inhibitors
International Journal of Hematology, 2005The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome.
Mark, Levis, Donald, Small
openaire +2 more sources
Tyrosine kinase inhibitors and the thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 2009Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire +2 more sources
Inhibitors of protein tyrosine kinases
Current Opinion in Biotechnology, 1995The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire +2 more sources
Neoadjuvant Tyrosine Kinase Inhibitors
Thoracic Surgery ClinicsNeoadjuvant tyrosine kinase inhibitor (TKI) therapy has appeal given the potential for early systemic disease control and tumor downstaging prior to surgery. Until recently, data has have come from smaller series with outcomes from larger trials, including NeoADAURA, ALNEO, and NAUTIKA1, reporting early results. Neoadjuvant use of TKI has been shown to
Gavitt A, Woodard +2 more
openaire +2 more sources
Small molecule tyrosine kinase inhibitors in glioblastoma
Archives of pharmacal research, 2020Gayoung Kim, Y. Ko
semanticscholar +1 more source
The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020
Bioorganic Chemistry, 2021Xiaoxia Liang, Zhongyin Yin, Yin Lizi
exaly